Editorial: Novel Immunological Biomarkers for Allogeneic HSCT Outcome.

Biomarkers, allogeneic transplantation, outcomes, graft-versus-host disease, cytokines, proteins, transplant-related mortality, immunological biomarkers Keywords: biomarkers; allogeneic transplantation; outcomes; graft-versus-host disease; transplant-related mortality; cytokines; immunological biomarkers; proteins EN biomarkers allogeneic transplantation outcomes graft-versus-host disease transplant-related mortality cytokines immunological biomarkers proteins N.PAG N.PAG 3 03/17/21 20210312 NES 210312 Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative treatment option for many malignant and non-malignant hematological disorders ([1], [2]). Mankarious et al. explore the potential applications of biomarkers to guide individualized treatment decisions in patients affected by acute and chronic GvHD. [Extracted from the article]